NCT05146336

CytOSorb TreatMent Of Critically Ill PatientS Registry

CytOSorb TreatMent Of Critically Ill PatientS Registry: International Registry on the Use of CytoSorb in the Critical Care Setting

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 3,000 (estimated)
• Sponsor: CytoSorbents, Inc · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based resource to measure and improve the quality of patient care

Conditions

• Septic Shock
• Acute Respiratory Distress Syndrome
• Trauma
• Rhabdomyolysis
• Cardiogenic Shock
• Pancreatitis
• Acute on Chronic Liver Failure
• Acute Liver Failure
• Burns
• Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Cytokine Release Syndrome (CRS)
• Extracorporeal Life Support
• Postoperative Endocarditis
• Hemophagocytic Lymphohistiocytoses
• Liver Transplant; Complications
• Infectious Disease
• Postoperative Vasoplegic Syndrome
• Drug Overdose
• Sepsis

Interventions

Type	Name	Description
DEVICE	CytoSorb	Sorbent hemoperfusion system

Timeline

• Start date: 2022-06-22
• Primary completion: 2032-06-01
• Completion: 2032-09-01
• First posted: 2021-12-06
• Last updated: 2025-09-11

Locations

28 sites across 6 countries: Austria, Germany, Italy, Poland, Portugal, Spain